Curis, Inc. - Common Stock (CRIS)
Frequently Asked Questions About Curis, Inc. - Common Stock (CRIS)
How can investors obtain information about Curis, Inc.?
Investors can obtain information about Curis, Inc. through the company’s official website, where they can access press releases, financial reports, and other investor resources. Additionally, they can consult financial news platforms and brokerage services for updates on the company’s stock performance.
How does Curis, Inc. approach drug development?
Curis, Inc. utilizes a research-driven approach to drug development, combining biological insights with cutting-edge technology. The company focuses on identifying and validating new targets, discovering small molecules, and advancing candidates through rigorous preclinical and clinical evaluation.
How does Curis, Inc. ensure the quality of its products?
Curis, Inc. adheres to strict regulatory standards and Good Manufacturing Practices (GMP) to ensure the quality and safety of its products. Rigorous testing, quality control procedures, and compliance with regulatory guidelines are integral to the company's operational processes.
How does Curis, Inc. fund its operations?
Curis, Inc. funds its operations through a combination of public equity offerings, government grants, and partnerships with other pharmaceutical companies. This diversified funding model helps to support its research and clinical development activities.
Is Curis, Inc. involved in any collaborations with academic institutions?
Yes, Curis, Inc. collaborates with several academic institutions to further its research initiatives. These partnerships foster innovation and allow Curis to access novel scientific insights and technologies.
What are some key products in Curis, Inc.'s pipeline?
Curis, Inc. has several key products in its pipeline, including its lead candidate, CUDC-907, which targets both histone deacetylase (HDAC) and PI3K. This candidate is designed for the treatment of various hematologic malignancies and solid tumors.
What are the primary areas of research for Curis, Inc.?
Curis, Inc. primarily focuses on the areas of oncology and targeted therapies. The company is committed to developing drugs that target specific cancer-related proteins and pathways to improve the efficacy of treatment and minimize side effects.
What does Curis, Inc. do?
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company leverages its expertise in targeted protein degradation, immune modulation, and small-molecule drug discovery to develop novel cancer therapies aimed at improving patient outcomes.
What impact has Curis, Inc. made in the oncology field?
Curis, Inc. has made significant contributions to the oncology field by developing innovative therapeutic candidates that target specific molecular pathways in cancer. The company aims to address unmet medical needs and improve treatment options for cancer patients.
What is the mission of Curis, Inc.?
The mission of Curis, Inc. is to provide innovative, effective therapies for patients with cancer, leveraging its scientific expertise and commitment to excellence in drug development to make a meaningful difference in cancer treatment.
What is the significance of the stock performance of Curis, Inc.?
The stock performance of Curis, Inc. can provide insight into investor confidence and the broader market perception of the company's growth potential. Investors closely monitor stock performance as it can be influenced by clinical trial results, regulatory approvals, and partnerships.
What is the ticker symbol for Curis, Inc.?
The ticker symbol for Curis, Inc. is CRIS. The stock is traded on the NASDAQ stock exchange, reflecting the company's status as a publicly traded biotechnology firm.
What partnerships does Curis, Inc. have?
Curis, Inc. has entered into various strategic partnerships with leading pharmaceutical and biotechnology companies to enhance its research capabilities and advance its clinical programs. Such collaborations often involve licensing agreements and co-development arrangements.
What regulatory approvals has Curis, Inc. received?
Curis, Inc. has received various regulatory approvals for its clinical trials from agencies such as the U.S. Food and Drug Administration (FDA). These approvals are crucial for advancing its promising therapies through clinical development.
What stage of development is Curis currently in?
As of now, Curis, Inc. is in various stages of clinical and preclinical development for its pipeline candidates. Some compounds are undergoing late-stage clinical trials, while others are in earlier phases of development.
When was Curis, Inc. founded?
Curis, Inc. was founded in 2000 as a biotechnology company dedicated to advancing targeted medicines for cancer treatment. Over the years, Curis has evolved and developed several promising therapies.
Where is Curis, Inc. headquartered?
Curis, Inc. is headquartered in Lexington, Massachusetts. This strategic location allows Curis to be in proximity to leading academic institutions and innovative biotechnology firms, facilitating collaboration and access to cutting-edge research.
Who are Curis, Inc.’s competitors?
Curis, Inc. faces competition from other biotechnology companies in the oncology space that are developing similar targeted therapies and immunotherapies. Prominent competitors may include companies specializing in novel cancer treatments, such as Amgen, Gilead Sciences, and other clinical-stage biotechs.
Who are the key executives at Curis, Inc.?
Key executives at Curis, Inc. include the Chief Executive Officer, Chief Financial Officer, and various heads of research and development. Their collective expertise drives the strategic vision and operations of the company.
What is the current price of Curis, Inc. - Common Stock?
The current price of Curis, Inc. - Common Stock is 1.160
When was Curis, Inc. - Common Stock last traded?
The last trade of Curis, Inc. - Common Stock was at 4:00 pm EDT on April 7th, 2025
What is the market capitalization of Curis, Inc. - Common Stock?
The market capitalization of Curis, Inc. - Common Stock is 106.25M
How many shares of Curis, Inc. - Common Stock are outstanding?
Curis, Inc. - Common Stock has 91.60M shares outstanding.